Академический Документы
Профессиональный Документы
Культура Документы
June 2017
1
FORWARD LOOKING STATEMENT
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995 and other securities laws. Forward-looking statements are not historical facts, and are based upon
managements current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain.
Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that
managements expectations, beliefs and projections will be achieved and actual results may differ materially from
what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks
and uncertainties that could cause actual performance or results to differ materially from those expressed in the
forward-looking statements, including risks detailed in Mazor Robotics Ltd.s (Mazor Robotics or the Company)
annual reports on Form 20-F filed with the U.S. Securities and Exchange Commission. The following solution is not
yet cleared for use: ArcAid device.
Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation
to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in
assumptions or changes in other factors affecting forward-looking information except to the extent required by
applicable securities laws. If the Company does update one or more forward-looking statements, no inference should
be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking
statements.
US Penetra6on
(end of Q1/17)
X X
X XX X X 104 Systems Installed
in the US
X 43 Mazor X Orders
since Launch
X
X 6 Customers with
X mul'ple system
X Bioskills Lab X orders
Renaissance
X Mazor X
X 16 systems ordered by
HCA hospital chain
mazo rro b o 'cs. co m 4
Hospital, Geographic and Procedure Diversity
5% 10%
9% 24%
20%
61% 19%
64% 12%
76%
Cross-
Surgical
Image modality Op6cal
SoZware Bone Robo6c Tool Data
Process- Image Navig-
Tools Mount Guidance Develop- Analy6cs
ing Registr- a6on
ment
a6on
Consistent Accuracy with Improved Outcomes Proven Reduction in Complications and Revisions (1)
Free-Hand Mazor
18.1%
5.2% 5.8%
0.9%
Complica'ons Revisions
Trend
Illustra'on
ordered
Capital Sales (List Prices) Per Case Revenue Per System Revenue
2017
Medtronic Mazor X Scan & Plan
Co-Development (Update)
2018* ArcAid
Futuris'c rod bending 2017
for Mazor X-Align plan Mazor X SIJ
Mazor X Lateral
2017 2018
Medtronic implant planning Mazor X Align
mazo rro b o 'cs. co m 15
Medtronic and Mazor Commercial Integration
Assuming Phase II (by Q1/18)
2016 ~ 2020*
Revenue 100% 100%
Income Statement
Operating Expenses
Research and development $5,736 $6,324 $1,792 $2,131
Selling and marketing $33,637 $24,947 $9,893 $6,873
General and administrative $5,697 $4,305 $1,571 $983
Total operating expenses $45,070 $35,576 $13,256 $9,987
% of revenue 124% 136% 113% 156%
Accelerating growth